Michael Doubek

Brno, JM, Czech Republic

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 181 publications

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti

Published: August 28, 2026

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Subtype-specific outcome after allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis: a registry study of the European competence network on mastocytosis.

Journal: Experimental hematology & oncology

Published: June 21, 2026

Longitudinal single-cell analysis reveals dynamic clonal competition and convergent evolution shaped by therapy sequencing in a young patient with chronic lymphocytic leukemia.

Longitudinal single-cell analysis reveals dynamic clonal competition and convergent evolution shaped by therapy sequencing in a young patient with chronic lymphocytic leukemia.

Journal: Haematologica

Published: May 15, 2026

Targeted gene expression profiling as a tool for diagnostic cell-of-origin determination and prognostic stratification in diffuse large B-cell lymphoma.

Targeted gene expression profiling as a tool for diagnostic cell-of-origin determination and prognostic stratification in diffuse large B-cell lymphoma.

Journal: Ceskoslovenska patologie

Published: April 17, 2026

Diffuse alveolar hemorrhage in primary antiphospholipid syndrome: A case series of six patients.

Diffuse alveolar hemorrhage in primary antiphospholipid syndrome: A case series of six patients.

Journal: Respiratory medicine and research

Published: March 20, 2026

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study.

Journal: Journal of hematology & oncology

Published: March 15, 2026

Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial.

Assessing an eHealth Intervention on Quality of Life in Patients With Chronic Lymphocytic Leukemia and Myelodysplastic Syndromes: The MyPal Randomized Controlled Trial.

Journal: JCO oncology practice

Published: August 25, 2025

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

Journal: Annals of hematology

Published: August 10, 2025

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Journal: Blood advances

Published: July 14, 2025

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.

Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.

Journal: Leukemia

Published: May 20, 2025

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study.

Circular RNA signature of aggressive CLL with t(14;19)(q32;q13). An ERIC study.

Journal: Journal of hematology & oncology

Published: April 15, 2025

Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.

Germline Jak2-R1063H mutation interferes with normal hematopoietic development and increases risk of thrombosis and leukemic transformation.

Journal: Leukemia

Published: January 31, 2025

Showing 1-12 of 181

Last Updated: 09/26/2026